Showing results (131-140 of 156) with videos related to
Sort By:
Pageof 16
Cytotherapy|May 14, 2017
Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasiaValerie D Roobrouck, Esther Wolfs, Michel Delforge, et al.BMJ Open|July 4, 2025
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocolSiddharth Chhajlani, Jelka Kuiper, Philippe Beutels, et al.EJNMMI Reports|May 14, 2025
Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CTHannes Leupe, Niloefar Ahmadi Bidakhvidi, Karolien Goffin, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2022
18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter StudyElin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.Therapeutic Advances in Medical Oncology|October 27, 2023
Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRIGéraldine Lens, Niloefar Ahmadi Bidakhvidi, Vincent Vandecaveye, et al.EJNMMI Research|August 7, 2013
18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot studyKimy M Emonds, Michel Koole, Cindy Casteels, et al.EJNMMI Research|June 1, 2023
Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patientsLennert Boeckxstaens, Elin Pauwels, Vincent Vandecaveye, et al.Journal of Neuroendocrinology|June 5, 2024
Clinical impact of using [18F]AlF-NOTA-octreotide PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trialHannes Leupe, Elin Pauwels, Timon Vandamme, et al.Journal of Neuroendocrinology|October 20, 2021
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumoursRodney J Hicks, Clarisse Dromain, Wouter W de Herder, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2025
Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 TrialLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.Pageof 16